QTRX vs RCEL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
QTRX exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness in operational efficiency and financial health. While the company maintains strong top-line revenue growth (24.7% YoY) and a healthy current ratio (2.84), these are overshadowed by a devastating profit margin of -77.14% and a consistent track record of missing earnings estimates. The stock is in a clear long-term downtrend, having lost over 94% of its value over five years, and currently trades at a significant discount to book value (P/B 0.55), suggesting a 'value trap' scenario.
RCEL presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) that masks severe underlying liquidity and solvency issues. The company exhibits negative shareholders' equity (Price/Book: -9.43) and a critical liquidity shortage with a current ratio of 0.57, indicating an inability to cover short-term obligations. Despite strong gross margins (82.13%) and bullish analyst targets, the fundamental trend is negative with shrinking revenue (-4.30%) and a consistent history of missing earnings estimates.
Compare Another Pair
Related Comparisons
QTRX vs RCEL: Head-to-Head Comparison
This page compares Quanterix Corporation (QTRX) and AVITA Medical, Inc. (RCEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.